Introduction
The myelodysplastic syndromes (MDS) are a group of disorders characterized by cytopenias, often in the presence of adequate or increased numbers of cells in the bone marrow, and an increased propensity to develop acute leukemia. 1 Death occurs more frequently from the consequences of chronic cytopenias than from transformation to acute myeloid leukemia (AML). [2] [3] [4] Several recent reports indicate that a high proportion of bone marrow (BM) cells are undergoing apoptosis in patients with MDS, [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] which may contribute to the cytopenias that occur in these disorders. A correlation between apoptosis and cytopenias in MDS has been observed in some studies but not in others. [6] [7] [8] [9] [10] [11] [12] [13] [14] There are several possible reasons for variability in correlation between the extent of apoptosis detected in the marrow and the clinical features of MDS. It is possible that in situ end labeling may not detect a proportion of apoptotic cells that can be identified by other methods. 16 Further, since apoptosis is a dynamic process, assays for apoptosis at one time point in complex tissues, such as the marrow, may not accurately reflect the total number of cells having undergone Correspondence: P Gupta, Hematology/Oncology Section 111E, VA Medical Center, One Veteran's Drive, Minneapolis, MN 55417, USA; Fax: +1 612 725 2149 Received 18 March 1998; accepted 8 September 1998 apoptosis over time. Certain assays may fail to detect cells at early stages of apoptosis, whereas cells at later stages of apoptosis may already have been rapidly removed by reticuloendothelial cells in the marrow. Moreover, the extent of apoptosis seen may depend on the proportions of residual normal hematopoietic cells and of blasts in the sample, since the former but not the latter may be apoptotic. Thus, paradoxically, a higher degree of apoptosis may be seen in marrows with low blast counts and a higher content of normal hematopoietic cells. 8 One major mechanism for apoptosis in both hematopoietic and non-hematopoietic cells is the Fas pathway. Fas is a tumor necrosis factor-receptor (TNF-R) family cell surface receptor that induces apoptosis when ligated by Fas ligand (FasL), a cell surface TNF family molecule. 17 Since normal hematopoietic cells express Fas receptor, [18] [19] [20] [21] [22] [23] [24] they may be susceptible to apoptosis triggered by FasL-expressing cells. Mature peripheral blood cells including neutrophils express high levels of Fas and are susceptible to Fas-mediated apoptosis, 23 whereas normal progenitors express low levels of Fas and are not susceptible to Fas-mediated apoptosis. 25 However, on normal CD34
+ hematopoietic cells, Fas expression is synergistically induced by TNF-␣ and interferon-␥ (IFN-␥), resulting in increased susceptibility of clonogenic, as well as primitive progenitors to Fas-mediated apoptosis. 18, 19, 26 In aplastic anemia, the increased expression of TNF-␤ and IFN-␥ in the BM is accompanied by increased Fas on CD34 + cells and increased susceptibility of clonogenic progenitors to Fas-mediated killing. 27 In addition, TNF-␣ expression is increased in the BM of patients with MDS, and correlates with the degree of apoptosis. 28 A proportion of BM and peripheral blood cells are derived from normal progenitors in MDS, 29, 30 indicating that residual normal hematopoiesis contributes to the maintenance of peripheral blood cells in patients with MDS. The finding that CD34 + cells, differentiating hematopoietic cells and stromal cells undergo increased apoptosis 6, 9, 10 suggests that cells derived from both the abnormal clone and those derived from normal progenitors may be apoptotic in MDS. Recent studies indicate that in MDS, the Fas pathway is functional and capable of inducing apoptosis in clonogenic progenitors when activated. Fas is expressed on CD34 + , CD33 + and glycophorin + cells in MDS, and both erythroid and granulocyte-macrophage colony-forming cells are susceptible to apoptosis induced by an agonist anti-Fas antibody. 7, 8 A variety of tumor cell types express FasL, the ligand for the Fas receptor. [31] [32] [33] [34] [35] Malignant cells appear to possess mechanisms to protect themselves against FasL-mediated apoptosis, while maintaining the ability to induce apoptosis in normal cells. 6, 35, 36 Recent reports indicate that FasL expression is increased in MDS. 15, 37 We hypothesized that the expression of FasL (1) is increased in the bone marrow of patients with MDS; (2) contributes to the cytopenias observed in these disorders by its effects on hematopoietic progenitors; and (3) cor-relates with cytopenia and prognosis. We demonstrate that FasL expression is significantly increased in MDS and AML, that FasL expressed by MDS marrow cells directly inhibits the growth of hematopoietic progenitors in vitro, and that FasL expression correlates with anemia and predicts transfusion requirements and survival in patients with MDS.
Methods

Patients
A cohort of 50 consecutive patients diagnosed with MDS and 10 with AML at the Minneapolis VA Medical Center from 1992-1997 were identified by retrospective review of BM pathology records. Clinical information, including features at presentation, clinical course and outcome, was obtained by chart review. The demographic characteristics of the patients and clinical features at presentation are shown in Table 1 . All the patients were males, reflecting the patient population at the Minneapolis VA Medical Center. The French-AmericanBritish (FAB) classification of the 50 patients with MDS was: RA (n = 4), RA with ringed sideroblasts (RARS; n = 6), RA with excess blasts (RAEB; n = 10), RAEB in transformation (RAEBT; n = 7), chronic myelomonocytic leukemia (CMML; n = 13), and unclassified MDS (n = 10). Forty patients required blood product transfusions: RBC (n = 19), platelets (n = 2), or both products (n = 19). To normalize RBC transfusion requirements over time, the total number of units of RBC transfused between the diagnosis of MDS and either death or transformation to AML were converted to the average number of units transfused per 6 months, as follows: Number of units transfused between diagnosis of MDS and death or transformation to AML/Time in months from diagnosis of MDS to death or transformation to AML × 6. Patients included in this study were treated with pyridoxine (n = 7), androgens (n = 1), prednisone (n = 1), hydroxyurea (n = 2), 6-thioguanine + cytosine arabinoside (n = 1), 5-azacytidine (n = 2), erythropoietin (EPO; n = 2), and folic acid (n = 4). The remaining patients received only 
Immunohistochemical staining for FasL
FasL expression was determined on BM samples that had been obtained at diagnosis of MDS, prior to treatment, by modification of a previous method. 31 Sections (5 m thick) were cut from bone marrow aspirate clots embedded in paraffin in B-5 fixative and mounted on poly-l-lysine-coated slides. The sections were deparaffinized in xylene, rehydrated through graded alcohols and demercurized in alcoholic iodine. Endogenous peroxidase activity was quenched by immersing the slides in 1.5% hydrogen peroxide for 10 min at room temperature, followed by rehydration through three changes of distilled water. To induce heat-induced epitope retrieval, slides were immersed in 10 mm citrate buffer (pH 6.0) in a pressure cooker which was heated to boiling at 12 psi for 10 min and then cooled to room temperature over 20 min. Nonspecific binding was blocked by incubating sections with 15 g/ml horse serum for 15 min at room temperature. The sections were then incubated for 1 h with 0.6 g/ml mouse MAb against residues 116-277 of human FasL (MAb clone 33; Transduction Laboratories, Lexington, KY, USA). Negative control sections were incubated with nonimmune mouse serum or ascites fluid diluted 1:400 in PBS. Following incubation for 30 min with horse anti-mouse secondary antiserum, sections were immunolabeled using an avidin-biotin-immunoperoxidase method (Vector Laboratories, Burlingame, CA, USA). The chromogen was a solution of 0.5 mg/ml 3,3Ј-diaminobenzidine tetrahydrochloride (DAB) and 0.009% hydrogen peroxide. Color development was terminated after 5 min by immersion in water. To differentiate iron deposits in hematopoietic cells, sections were immersed in equal parts of 5% potassium ferrocyanide and 5% HCl for 5 min. Sections were finally counterstained with hematoxylin, dehydrated and coverslipped with permount. FasL expressing cells were identified by granular intracytoplasmic staining. In each section, 1000 cells were scored for FasL expression by a pathologist (GAN) who was blinded to the FAB subtype and clinical information regarding the patients.
Additional sections from some of the same BM samples were immunostained using another anti-FasL primary antibody (Q20, a rabbit polyclonal directed against N-terminal amino acid residues 2-21; Santa Cruz Biotechnology, Santa Cruz, CA, USA). Heat-induced epitope retrieval was induced by incubation of the sections in 10 mm citrate buffer for 20 min at 100°C, at atmospheric pressure. Sections were incubated with 1 g/ml of the primary antibody for 45 min, and developed with a multi-link secondary antibody using the Vector Elite kit (Vector). To further confirm the specificity of the staining for FasL, blocking experiments were performed by pre-incubation of the sections with a four-fold excess of a blocking peptide (amino acid residues 2-21 of FasL).
The immunohistochemistry technique described can be used on BM clot specimens which have been fixed in either B5 or formalin, but not in Zenker's or Bouin's fixatives. Also, the process used for decalcification of BM trephine specimens renders FasL undetectable by this method.
Immunoblotting for FasL
BM was aspirated in preservative-free heparin from the posterior iliac crest of patients with MDS or healthy volunteers after obtaining written informed consent. The study was approved by the VA Medical Center Human Subjects Subcommittee. The BM aspirates were immediately subjected to Ficoll-Hypaque (sg 1.077) centrifugation. BM mononuclear cells (BMMNC) at the interface were aspirated, washed three times, counted and resuspended in Iscove's modified Dulbecco's medium (IMDM) + 20% fetal calf serum + 20% dimethylsulfoxide, and stored in liquid nitrogen following controlled rate freezing, until used in co-culture with normal CD34 + /HLA-DR + cells or for immunoblotting. For immunoblotting, the frozen cells were rapidly warmed to 37°C, diluted in warm IMDM, and immunoblotting performed as described. 31 Briefly, BMMNC were pelleted and lysed in 1 ml of 50 mm Tris-HCl (pH 7.5), 250 mm NaCl, 5 mm EDTA, 0.1% NP40, 50 mm NaF and 1 mm phenylmethylsulfonylfluoride. Approximately 30 g of total protein from each sample was electrophoresed on 12.5% SDS-PAGE gel, and electroblotted on to a nitrocellulose membrane. The membranes were blocked using 5% dry milk + 1% BSA in PBS, incubated with 1:1000 dilution of murine anti-human FasL MAb (Transduction Laboratories) at 4°C overnight and then with a rabbit anti-murine IgG antibody (PharMingen, San Diego, CA, USA). Protein bands were visualized by enhanced chemiluminescence as recommended by the manufacturer (Amersham, Arlington Heights, IL, USA).
In parallel, membranes were incubated with 1.5 g/ml of a different primary antibody (anti-FasL IgG MAb clone G-247-4; PharMingen) for 1 h at room temperature. Following incubation with a secondary antibody, FasL was detected using an enhanced chemiluminescence kit (Amersham). A pGEX2TK-FasL fusion protein (size approximately 60 kDa), possessing the full-length recombinant human FasL protein with a GST leader was run as a positive control, to confirm the capability of the antibody to recognize human FasL.
Effect of FasL expressed by MDS BM cells on growth of clonogenic progenitors
CD34
+ /HLA-DR + (DR + ) cells were purified from bone marrow aspirates taken from normal adult donors, by sequential Ficoll-Hypaque (sg 1.077) centrifugation, Ceprate-LC (CellPro, Bothell, WA, USA) CD34-biotin immunoadsorption column selection and flow cytometry, as previously described. 38 To simulate the effect of increased levels of TNF␣ found in the marrow in MDS, 28 the DR + cells were suspended at a concentration of 100 000/ml in long-term bone marrow culture (LTBMC) medium (12.5% FCS, 12.5% horse serum, 2 mm lglutamine, 1000 U/ml penicillin, 100 U/ml streptomycin and 10 −6 m hydrocortisone) supplemented with 100 ng/ml TNF␣ (Sigma) and 10 ng/ml interleukin (IL)-3 (R&D Systems, Minneapolis, MN, USA) and incubated at 37°C in 5% CO 2 atmosphere for 48 h.
For co-cultures of DR + cells with cell lysates of MDS BMMNC, the frozen cells were rapidly warmed to 37°C and diluted in warm IMDM. The cells were pelleted gently, resuspended in IMDM at a concentration of 25 × 10 6 /ml and lysed by snap-freezing and thawing three times. Lysates from 2 × 10 5 or 2 × 10 6 MDS BMMNC were mixed with 2000 DR + cells in IMDM + 10% FCS + 10 ng/ml TNF␣ + 10 ng/ml interleukin-3 (IL-3) and incubated at 37°C in 5% CO 2 for 18 h.
In some cultures, the MDS cell lysates were incubated with either 10 g/ml recombinant FasFc protein (R&D Systems), 50 g/ml neutralizing anti-TNF␣ antibody (R&D Systems), or both, for 1 h at room temperature, to block the FasL 39 and TNF␣ present, prior to addition of the DR + cells to the lysates. For control cultures, DR + cells were incubated with the cytokines in the absence of cell lysates. Following the incubation, cells were washed once with IMDM + 20% FCS to remove cytokines, cell debris and FasFc, and plated in semisolid methylcellulose cultures supplemented with 3 U/ml EPO and 5 ng/ml IL-3. In cultures examining the effect of FasFc protein and anti-TNF␣ antibody, additional FasFc (0.5 g/ml) and anti-TNF␣ antibody (2.5 g/ml) were added directly to the methylcellulose medium. Colonies were scored after 14 days. 40 
Statistics
Data were entered on and analyzed using an SPSS software package. Mean differences between groups were compared using either the t-test or ANOVA. Correlations of interval scale variables were analyzed using linear regression. Overall survival by FasL expression (FasL р12% and FasL Ͼ12%) was analyzed by the Kaplan-Meier method 41 and compared using the log-rank statistic. In addition, the correlation between % FasL expression and overall survival was analyzed using Cox regression. Results were expressed as the mean ± s.e.m.
Results
FasL expression is increased in MDS and AML
We examined by immunohistochemistry (Figures 1 and 2 ) the expression of FasL in the BM of patients with MDS, AML developing in patients with MDS (secondary AML), de novo AML and age-and sex-matched normal controls. Immunohistochemistry was performed using two separate anti-FasL antibodies, directed against a C-terminal epitope (MAb clone 33; Figure 1 ) or an N-terminal epitope of FasL (polyclonal antibody Q20; Figure 2 ). There was a high degree of correlation (r = 0.97) between the percentage of FasL positive cells (normal controls, MDS and AML) detected by the two antibodies, MAb clone 33 and polyclonal Q20 (data not shown). In the BM of normal controls (n = 6), a uniformly low level of FasL expression was detected (6 ± 1% positive cells; range 3-9%) and was mostly confined to lymphocytes (Figures 1a and  3a) . In contrast, a wide range of FasL expression was seen in the BM of patients with MDS (n = 50; 17 ± 2% positive cells; range 2-51%; Figures 1b, 1c, 2a, 2c and 3a) , which was higher than the controls (p = 0.02). FasL expression in MDS was seen in erythroblasts, myeloblasts, megakaryocytes, maturing myeloid precursors and dysplastic cells, and was not confined to lymphocytes (Figures 1 and 2) . Mature neutrophils and erythroid normoblasts did not express detectable FasL. The staining in both MDS and AML BM cells by the Q20 antibody was almost completely blocked by pre-incubation of the sections with a peptide (amino acids 2-12 of FasL) comprising the epitope for the Q20 antibody (Figures 2b, d and f) .
FasL expression in MDS was further confirmed by immunoblot analysis of BMMNC. A protein of the expected size for FasL (37 kDa) was recognized by a murine anti-human FasL antibody (MAb clone 33) in lysates from MDS BMMNC (Figure 1f) . The level of FasL protein expression was signifi- cantly higher in MDS than in normal control BMMNC, using equivalent quantities of total protein from cell lysates. FasL (37 kDa) was also detected in MDS BMMNC by immunoblotting with another primary antibody (anti-FasL IgG MAb clone G-247-4, PharMingen), which also recognized the 60 kDa recombinant FasL fusion protein (Figure 2g ). Taken together, these results indicate that FasL is expressed in BM cells in both MDS and AML.
In the BM of patients with de novo AML (n = 10), an extremely high proportion of cells showed FasL expression (56 ± 9%; range 10-97%; Figures 1d, 2e and 3a) which was higher than that found in controls (P = 0.001) and patients with MDS (P Ͻ 0.001). FasL expression in AML was largely seen in the blast cells, which showed intense positivity for the protein (Figures 1d and 2e) . In all three patients studied, FasL expression increased at least three-fold upon transformation of MDS to secondary AML (Figure 3b) . In three additional patients with secondary AML, FasL expression ranged from 56 to 86% (initial diagnostic MDS marrows were not available for FasL staining in these patients). As in de novo AML, expression of FasL was seen largely in the blasts in secondary AML. The overall FasL expression in secondary AML (n = 6; 48 ± 13%; range, 9-86%) was comparable to de novo AML.
FasL expression correlates with FAB subtypes of MDS
A significant correlation was observed between FasL expression and FAB subtype groups of MDS:RA/RARS (9 ± 3% FasL positive cells), CMML (14 ± 3%), RAEB/RAEBT (20 ± 3%) and unclassified MDS (22 ± 4%); P = 0.028 (Figure 4a) . The high expression of FasL in unclassified MDS was somewhat surprising. However, patients included in the unclassified category had significant dysplasia in all three lineages, even though the proportion of blasts in the BM was Ͻ5%. The presence of dysmegakaryopoiesis or dysgranulopoiesis has previously been shown to adversely impact survival in MDS. 42 The majority of patients with unclassified MDS experienced a short survival in our study. BM cytogenetic analysis was available for 38 patients. In the patients who had detectable abnormalities, FasL expression correlated directly with the percentage of abnormal metaphases on cytogenetic analysis (P = 0.022; Figure 4b ). This suggests that FasL expression may correlate directly with the proportion of the marrow replaced by the progeny of the abnormal clone in MDS.
The FasL expressed by MDS cells inhibits the growth of clonogenic progenitors
In agreement with a recent report, 15 we observed FasL expression in myeloid, erythroid and mononuclear cells in MDS. We therefore examined if the FasL expressed by cells in MDS BM is functionally active in inhibiting the growth of hematopoietic progenitors. A significant and dose-dependent inhibition of the growth of clonogenic progenitors was seen in the presence of MDS BMMNC lysates (Figure 5a ). The growth of erythroid BFU-E as well as myeloid CFU-GM progenitors was inhibited, as reflected in inhibition of the total numbers of colonies formed. To examine if this inhibition was mediated by TNF␣, FasL or both, we evaluated the effect of addition of neutralizing anti-TNF␣ antibody, soluble FasFc protein (which specifically binds and blocks FasL) 31, 39 or both, in presence or absence of MDS cell lysates (Figure 5b ). In the absence of MDS cell lysates, neither the anti-TNF␣ antibody nor FasFc altered colony formation significantly. However, the inhibition of progenitor growth by MDS cell lysates was largely prevented by pre-incubation of the MDS cell lysates with FasFc, but not anti-TNF␣. The simultaneous addition of both FasFc and anti-TNF␣ did not further augment progenitor growth over that seen with FasFc alone. Using DR + cells from the same donors and cell lysates from the same MDS patients, we observed that the frequency of apoptotic cells in the DR + population (detected by the TUNEL assay or by annexin V staining) increased from 3% in controls to 10% in the presence of the MDS lysate, but was reduced to 6% by preincubation of the lysate with FasFc (data not shown).
Expression of FasL correlates with anemia in MDS
We next examined if FasL expression in the initial diagnostic BM of the 50 patients with MDS correlated with features of the clinical presentation and the subsequent disease course. FasL expression in the initial diagnostic BM was higher in patients with an initial hemoglobin Ͻ10 g/dl vs hemoglobin у10 g/dl (20 ± 3% vs 13 ± 2%, respectively; P = 0.03; Figure  6a ). Also, there was a direct correlation between FasL expression in the initial diagnostic BM and the average number of units of pRBC transfusions required per 6 months over the subsequent disease course (P = 0.039). Thus, patients with high FasL expression required more pRBC transfusions than patients with low FasL expression. There was a trend towards higher FasL expression in the BM of patients with more severe Figure 6 (a) Correlation of FasL expression with hemoglobin. FasL expression at diagnosis was correlated with hemoglobin at diagnosis. Comparison between Hb Ͻ10 g/dl and Hb у10 g/dl: P = 0.031. (b) Overall survival of patients expressing low and high levels of FasL at diagnosis. The overall survival stratified by FasL expression (FasL р12% and FasL Ͼ12%) from diagnosis of MDS (n = 50) was estimated by the Kaplan-Meier method 41 and compared using the log-rank test. Comparison between FasL р12% and FasL Ͼ12%: P = 0.035. neutropenia, though this did not achieve statistical significance (P = 0.06). No correlation was detected between FasL expression and age, platelet count, need for platelet transfusions, lactate dehydrogenase level, marrow cellularity, percentage of blasts, type of therapy or response to therapy.
FasL expression predicts survival in MDS
FasL expression was predictive of survival in the 50 MDS patients studied (median survival 28 months for FasL р12% vs 13 months for FasL Ͼ12%; P = 0.035; Figure 6b ). The 2-year survival was 60 and 21%, respectively. FasL expression also correlated directly with survival of these 50 patients as a single group (P = 0.04 by Cox regression analysis). A number of studies have confirmed the prognostic significance of the Bournemouth scoring system, in which a score from 0-4 is assigned based on hemoglobin, neutrophil count, platelet count and blast percentage at diagnosis. 3 We observed a significant correlation between Bournemouth score and survival in our patients (P = 0.019 by Cox regression analysis). The expression of FasL directly correlated with the Bournemouth prognostic score (P = 0.02). That FasL expression correlates with an independent, validated prognostic scoring system further suggests that it may have potential value in predicting the survival of patients with MDS.
Discussion
Recent reports demonstrate that the response of cytopenias to EPO and granulocyte colony-stimulating factor (G-CSF) therapy 43 or to inhibition of TNF-␣ is associated with reduction in the proportion of apoptotic cells in the BM. 10, 22, 44 These studies indicate that apoptosis is a clinically important phenomenon in MDS. Our studies demonstrate a correlation between the expression of FasL, the molecule which triggers Fas-mediated apoptosis, and the clinical features and prognosis of MDS. We further show that FasL expressed in MDS BM directly inhibits the growth of clonogenic hematopoietic progenitors. A recent report 15 demonstrating that the apoptotic (TUNEL positive) cells in MDS BM express both Fas receptor and Fas ligand, further supports our results.
We observed that apoptosis of FACS sorted DR + cells was increased in the presence of MDS cell lysates. However, since only a proportion of cells in the DR + population are clonogenic progenitors, increased apoptosis in the DR + population could not be used to conclude that similar and equivalent effects were occurring in the progenitors within that population. We therefore used a functional culture assay to directly demonstrate that FasL expressed by MDS cells is functionally active in inhibiting the growth of clonogenic progenitors, and that this effect can largely be blocked by addition of soluble FasFc protein.
The susceptibility of maturing cells to FasL-induced apoptosis may itself be increased by upregulated Fas expression on these cells 19, 26, 27 that is induced by higher levels of cytokines including TNF-␣ in MDS marrow. 28 In addition, the elevated ratio of c-myc to bcl-2 in CD34
+ progenitors in MDS 10 may increase their susceptibility to FasLinduced apoptosis. Indeed, interleukin-1␤ converting enzmye (ICE/caspase-1) protease pathway inhibitors that block the downstream cascade activated by the Fas receptor or other apoptosis signaling pathways reduce the in vitro apoptosis of MDS cells. 45 Nevertheless, the ability of FasL to induce apoptosis in a given cell may be modulated positively or negatively by a number of additional intracellular proteins and enzymes downstream from Fas, which may themselves be perturbed in dysplastic and malignant cells.
In the present study, FasL expression correlated significantly with anemia and pRBC transfusion requirements, whereas a trend towards correlation with neutropenia was found. We observed that FasL is expressed in nucleated erythroid cells in MDS marrow. Interestingly, Bouscary et al 8 reported that Fas was expressed on erythroid cells, that erythroid cells were apoptotic in at least some patients and that the growth of erythroid progenitors was susceptible to inhibition by an agonist anti-Fas antibody. Lepelley et al 9 observed that in several cases of MDS, apoptosis was predominantly seen in erythroid progenitors. Normal erythroid progenitors are also susceptible to FasL-mediated apoptosis following IFN-␥ induced upregulation of Fas receptor. 26 It is therefore possible that erythroid cells are particularly susceptible to Fas pathwaymediated suicide or fratricide.
The increased expression of FasL by malignant cells may also permit tumors to escape host T cell-mediated immunologic surveillance by inducing apoptosis in Fas receptor expressing T cells. [31] [32] [33] [34] Among the hematological malignancies, increased FasL expression on myeloma cells has been shown to induce apoptosis of T cells, while the myeloma cells themselves are resistant to FasL-induced apoptosis. 35 FasL expression is also increased in malignant lymphomas, Hodgkin's disease and large granular lymphocyte leukemia. 46, 47 Whether the increased expression of FasL contributes to the survival and growth of leukemic or dysplastic clones is unknown.
The absence of a single and uniformly present marker for the abnormal cells in MDS precluded a definitive study of whether FasL expression is increased on only the abnormal cells, only normal cells or both. Many of the FasL-expressing cells had dysplastic morphological features. Furthermore, FasL expression correlated directly with the proportion of abnormal metaphases on cytogenetic analysis. These data indicate that at least a significant proportion of FasL expression occurs in the abnormal cells. Additional studies are needed to determine if FasL expression is increased in the residual normal cells as well.
In summary, our studies indicate that: (1) BM cells express an elevated level of FasL in MDS; (2) there is a progressively increasing expression of FasL in the marrow over the spectrum from normal through MDS to AML; (3) FasL expressed in MDS BM cells is functionally active and inhibits the in vitro growth of normal clonogenic progenitors; and (4) increased FasL expression is predictive of anemia, increased RBC transfusion requirements and shorter survival in MDS. These studies lead us to speculate that cytopenias which occur in MDS (and perhaps in malignancies such as AML) may at least in part be a result of FasL-induced inhibition of hematopoiesis, and not simply a 'crowding out' of normal hematopoietic cells by the abnormal clone. Our studies provide the rationale for trials of pharmacological strategies that block the Fas-FasL pathway, to attempt to ameliorate cytopenias in MDS.
